-
1 Comment
CSL Limited is currently in a long term downtrend where the price is trading 1.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.
CSL Limited's total revenue sank by 0.0% to $2B since the same quarter in the previous year.
Its net income has dropped by 0.0% to $624M since the same quarter in the previous year.
Finally, its free cash flow grew by 178.9% to $878M since the same quarter in the previous year.
Based on the above factors, CSL Limited gets an overall score of 2/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
Sector | Healthcare |
Industry | Biotechnology |
ISIN | AU000000CSL8 |
Market Cap | 69B |
---|---|
PE Ratio | 29.32 |
Target Price | None |
Dividend Yield | 1.7% |
Beta | 0.35 |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CSJ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025